Desert Chamomile From Algeria Fights Bacteria, Fungi, and Cognitive Decline in Early Lab Tests

Chamomile has been steeped into cups for thousands of years, but a new round of preclinical research suggests that a desert-growing Algerian variety of the plant may do considerably more than calm an anxious stomach. Laboratory tests reported by Daily Beirut found that an extract from this specific chamomile strain inhibited a clinically troublesome bacterium, a common fungal pathogen, a carbohydrate-digesting enzyme tied to blood sugar control, and enzymes associated with cognitive decline. The researchers are careful to frame this as early-stage work, but the breadth of activity across four distinct biological targets in a single plant extract is worth paying attention to.

Algerian Chamomile Extract Blocks Staphylococcus aureus and Candida albicans

The headline findings from the laboratory tests are antimicrobial. The Algerian chamomile extract inhibited the growth of Staphylococcus aureus, a bacterium responsible for a wide range of infections from skin wounds to life-threatening sepsis, and Candida albicans, the fungal species behind many oral, vaginal, and systemic infections. Both pathogens are of growing clinical concern because resistance to conventional antimicrobials is rising. Chemical analysis of the extract identified elevated levels of polyphenols and flavonoids compared with chamomile more broadly, along with two specific bioactive compounds: caffeic acid and apigenin-7-O-glucoside. Caffeic acid is a phenolic compound with established antioxidant activity; apigenin-7-O-glucoside is a glycosylated form of apigenin, a flavonoid already linked to sedative and anti-inflammatory effects in prior research. The desert environment in which this Algerian variety grows may be driving the higher polyphenol load, since plants under environmental stress tend to upregulate secondary metabolite production as a defensive response.

Blood Sugar and Brain Enzyme Inhibition Signal Wider Potential

Beyond the antimicrobial results, the extract reduced the activity of alpha-amylase, the enzyme that breaks down complex carbohydrates into sugars in the digestive tract. Slowing alpha-amylase can blunt the post-meal spike in blood glucose, which is the same mechanism exploited by some pharmaceutical antidiabetic drugs. The extract also inhibited enzymes associated with cognitive decline in neurodegenerative diseases, a finding that places it in the same broad category of research being pursued for conditions like Alzheimer's disease. Separately, animal experiments using mice with induced inflammation confirmed a significant reduction in swelling, adding a direct anti-inflammatory data point to the in vitro results. A systematic review and meta-analysis of randomized clinical trials on chamomile's anti-inflammatory effects has already documented pain reduction and decreased mucositis severity in human subjects, which gives the animal finding at least some broader context, though the Algerian desert variety has not been tested in humans.

Why Apigenin Makes This More Than a Folk Remedy Story

Chamomile as a genus contains over 120 identified constituents, including terpenoids such as alpha-bisabolol and chamazulene, as well as a range of phenolic compounds. Apigenin, the flavonoid backbone of apigenin-7-O-glucoside identified in the Algerian extract, is the compound most studied for chamomile's neurological effects: it binds to benzodiazepine receptors in the brain, which explains the sedative action long attributed to chamomile tea. A long-term randomized clinical trial on chamomile for generalized anxiety disorder found modest but real anxiolytic effects, along with trends toward lower blood pressure and weight loss that the authors said warrant further study. That human-level evidence for apigenin-class activity makes the neuroprotective enzyme inhibition found in the Algerian extract more biologically plausible, even if it remains unconfirmed in people. A comprehensive review of chamomile's therapeutic applications also documents in vitro antioxidant and anticancer activity against prostate, breast, and lung cancer cell lines, pointing to how densely this plant's chemistry interacts with human biology across multiple pathways.

Key Limitations: Everything Here Is Preclinical

The researchers behind the Algerian chamomile work are explicit about the boundaries of what they have shown. Every finding, the antimicrobial inhibition, the enzyme activity reduction, the anti-inflammatory effect in mice, comes from laboratory or animal models. None of it has been tested in a clinical trial in humans. Translating a promising in vitro or animal result into an effective, safe human therapy is the step where most such candidates fail, and chamomile is no exception. A broad NIH-hosted review of chamomile's therapeutic potential stresses that robust clinical trials are still needed to establish both efficacy and safety, particularly in vulnerable populations such as pregnant women and people on blood thinners, since chamomile can interact with anticoagulant medications. The US FDA has classified chamomile as generally regarded as safe (GRAS) for food use, but that designation does not extend to therapeutic doses or concentrated extracts.

What Comes Next for Algerian Chamomile Research

The researchers frame their findings as a foundation for compound development rather than a finished product. The next steps would involve isolating caffeic acid and apigenin-7-O-glucoside individually to confirm which compound is responsible for each observed effect, then testing those isolates in animal disease models before any human work could begin. The neuroprotective enzyme inhibition finding is perhaps the most intriguing thread, given how few effective treatments exist for neurodegenerative diseases and how actively researchers are searching for new scaffolds. The alpha-amylase inhibition result could also attract attention from researchers working on type 2 diabetes management through dietary enzyme modulation. For now, the Algerian desert chamomile study adds a geographically specific data point to a growing body of work showing that regional plant varieties, shaped by harsh local environments, may carry pharmacological profiles distinct from their more widely studied relatives. The gap between these results and a clinician's prescription pad is large, but the compounds identified give researchers a concrete starting point.

Evidence rating

INVESTIGATIONAL — 51/100

Caveats:

• All findings are from in vitro (lab) and animal (mouse) experiments — no human trials have been conducted.
• This is a single, unreplicated preclinical study; results may not translate to humans.
• The source article is a news summary, not a peer-reviewed publication; the original study's full methodology and peer-review status are unverifiable from this report.

Preclinical study combining in vitro assays and a mouse inflammation model. Results reflect laboratory and animal conditions only and cannot establish efficacy or safety in humans. The study has not been independently replicated, and the full peer-reviewed source was not available for review.

References

1. (2026). Algerian Chamomile Study Reveals Therapeutic Benefits – Daily Beirut. https://dailybeirut.com/en/technology-and-science/algerian-chamomile-shows-promising-therapeutic-properties-in-recent-study/
2. Jason Valmy, Stephanie Greenfield, Satoru Shindo, Toshihisa Kawai, Jorge Cervantes, Bo-Young Hong (2025). Anti-inflammatory effect of chamomile from randomized clinical trials: a systematic review and meta-analyses. Pharmaceutical Biology. https://doi.org/10.1080/13880209.2025.2530995
3. Jun J. Mao, Sharon X. Xie, John R. Keefe, Irene Soeller, Qing S. Li, Jay D. Amsterdam (2016). Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. https://doi.org/10.1016/j.phymed.2016.10.012
4. A Comprehensive Study of Therapeutic Applications of Chamomile. mdpi.com. https://www.mdpi.com/1420-3049/27/20/6905
5. Chamomile: A herbal medicine of the past with bright future – PMC – NIH. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC2995283/